From the Journals

Cisplatin-Free Toripalimab Tested for Head and Neck Cancer

Researchers note reduced rates of vomiting, fatigue, anemia, and leukopenia compared with standard therapy.

Share

  • 1

    Phase 3 trial of toripalimab in nasopharyngeal carcinoma.

  • 2

    Median follow-up: 37 months.

  • 3

    3-year FFS: 88.3% (cisplatin-sparing) vs 87.6% (standard).

  • 4

    Fewer adverse events in cisplatin-sparing group.

  • 5

    532 patients enrolled across 13 hospitals in China.

  • 6

    Limitations: patient demographics and lack of long-term toxicity data.

  • 7

    Future trials assess PD-1 blockade combinations.

  • 8

    No conflicts of interest reported.

Original Source(s)

Cisplatin-Free Toripalimab Tested for Head and Neck Cancer

Researchers note reduced rates of vomiting, fatigue, anemia, and leukopenia compared with standard therapy.

  • by Stanley Gajete

  • September 4, 2025

  • 3 min

Related Content

Tracking Opioid Refills After Surgery

Researchers evaluated perioperative and postdischarge factors associated with opioid refill prescriptions during the first 90 days after inpatient otolaryngology–head and neck surgery.

Neck Swelling, Dysphagia, and Jaw Pain: What’s Your Diagnosis?

A rare carotid artery pseudoaneurysm complicated by MRSA infection, septic arthritis, and an incidental thigh tumor challenged clinicians but was successfully treated with surgery and targeted antibiotics.

Chronic Cough Linked to GLP-1 Agonists 

New research suggests popular diabetes and weight-loss drugs may trigger persistent respiratory symptoms beyond their known gastrointestinal effects.